AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reissued by equities research analysts at FBR & Co in a research report issued to clients and investors on Thursday, July 13th. They presently have a $3.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price target would suggest a potential upside of 9.09% from the company’s current price.
AVEO has been the subject of several other research reports. ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. Piper Jaffray Companies set a $2.00 price target on AVEO Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Finally, Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.75 on Thursday. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $3.19. The firm’s market capitalization is $303.50 million. The company’s 50 day moving average price is $2.20 and its 200 day moving average price is $1.07.
A number of large investors have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC acquired a new stake in AVEO Pharmaceuticals during the second quarter worth $289,000. Paloma Partners Management Co bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $184,000. UBS Oconnor LLC bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $291,000. Sabby Management LLC bought a new position in AVEO Pharmaceuticals during the first quarter valued at about $513,000. Finally, Renaissance Technologies LLC raised its position in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares in the last quarter. 51.04% of the stock is owned by hedge funds and other institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.